ArticleFEBS letters2022
The 3D-structure, kinetics and dynamics of the E. coli nitroreductase NfsA with NADP
Article in FEBS letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Cloning, purification and possible use of a Bacillus nitroreductase in biotechnological applications.Scientific reports · 2026Article
- Nitroreductase-triggered indazole formation.Nature communications · 2026Article
- Novel TdsD nitroreductase: characterization of kinetics and substrate specificity.Biotechnology letters · 2025Article
- A reduction-secretion system contributes to roxarsone (V) degradation and efflux in Brevundimonas sp. M20.BMC microbiology · 2025Article
- Crystal structures of NAD(P)H nitroreductases from Klebsiella pneumoniae.Acta crystallographica. Section F, Structural biology communications · 2024Article
- Improving nitrofurantoin resistance prediction inAntimicrobial agents and chemotherapy · 2024Article
- Oxygen-insensitive nitroreductase E. coli NfsA, but not NfsB, is inhibited by fumarate.Proteins · 2023Article
- Structure and Dynamics of ThreeInternational journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Nitroreductases activate nitroaromatic antibiotics and cancer prodrugs to cytotoxic hydroxylamines and reduce quinones to quinols. Using steady-state and stopped-flow kinetics, we show that the Escherichia coli nitroreductase NfsA is 20-50 fold more active with NADPH than with NADH and that product release may be rate-limiting. The crystal structure of NfsA with NADP
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.